February 1, 1992Clinical Science
Responsiveness of superficial hand veins to α-adrenoceptor agonists in insulin-dependent diabetic patients
Key result
Symptomatic diabetic patients required significantly lower doses of noradrenaline for half-maximal venoconstriction compared to healthy controls (geometric mean 2.14 vs 6.61 ng/min, P=0.032).
Why the study?
Does local infusion of alpha-adrenoceptor agonists reveal differences in venous responsiveness between diabetic patients with autonomic neuropathy and healthy controls?
Population
Insulin-dependent diabetic patients with and without symptomatic autonomic neuropathy, and healthy control…
Comparison
Local infusions of noradrenaline and… vs Healthy control subjects
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
May indicate heightened venous alpha-adrenergic sensitivity in symptomatic diabetic neuropathy; hypothesis-generating for uptake mechanisms, requiring prospective validation.
Study Design
Type
Observational
Structured PICO
Does local infusion of alpha-adrenoceptor agonists reveal differences in venous responsiveness between diabetic patients with autonomic neuropathy and healthy controls?
P
Population
Insulin-dependent diabetic patients with and without symptomatic autonomic neuropathy and healthy control subjects.
E
Exposure
Local infusions of noradrenaline and phenylephrine into peripheral veins
C
Comparator
Healthy control subjects
O
Outcome
Dose required for half-maximal venoconstriction (ED50) measured by dorsal hand vein compliance techniquesurrogate
Main Result
Absolute Event Rate: 2.14% vs 6.61%
p-value: p=0.032
Vascular supersensitivity to catecholamines in diabetic autonomic neuropathy appears to be primarily determined by decreased neuronal catecholamine uptake rather than a postsynaptic increase in alpha-adrenoceptor stimulation.
Cite This Study
Eichler et al. (1992) conducted an observational in Insulin-dependent diabetes with and without autonomic neuropathy. Symptomatic diabetic autonomic neuropathy vs. Healthy control subjects was evaluated on Dose of noradrenaline for half-maximal venoconstriction (ED50) (p=0.032). Symptomatic diabetic patients required significantly lower doses of noradrenaline for half-maximal venoconstriction compared to healthy controls (geometric mean 2.14 vs 6.61 ng/min, P=0.032).